Prevalence of sulfadoxine-pyrimethamine resistance-associated mutations in dhfr and dhps genes of Plasmodium falciparum three years after SP withdrawal in Bahir Dar, Northwest Ethiopia

Acta Tropica

Volumn 128, Issue 3, 2013, Pages 636-641

  Hailemeskel, Elifaged ^a   Kassa, Moges ^b   Taddesse, Gemechu ^b   Mohammed, Hussien ^b   Woyessa, Adugna ^b   Tasew, Geremew ^b   Sleshi, Markos ^b   Kebede, Amha ^b   Petros, Beyene ^c  

^a WOLLO UNIVERSITY   (Ethiopia)

^b ETHIOPIAN PUBLIC HEALTH INSTITUTE   (Ethiopia)

^c ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

Bahir Dar; Dihydrofolate reductase; Dihydropteroate synthase; Drug resistance; P. falciparum; Sulfadoxine pyrimethamine

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; PYRIMETHAMINE PLUS SULFADOXINE;

BLOOD; DISEASE PREVALENCE; DISEASE SPREAD; DISEASE VECTOR; DRUG RESISTANCE; MALARIA; MUTATION; PARASITE;

ADULT; ALLELE; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD SAMPLING; CODON; CONTROLLED STUDY; DHFR GENE; DHPS GENE; DOT HYBRIDIZATION; DOWN REGULATION; ETHIOPIA; FEASIBILITY STUDY; FEMALE; GENE; GENE MUTATION; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; WILD TYPE;

ETHIOPIA;

PLASMODIUM FALCIPARUM;

BAHIR DAR; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; DRUG RESISTANCE; P. FALCIPARUM; SULFADOXINE-PYRIMETHAMINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DIHYDROPTEROATE SYNTHASE; DNA, PROTOZOAN; DRUG COMBINATIONS; DRUG RESISTANCE; ETHIOPIA; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; MUTATION, MISSENSE; NUCLEIC ACID HYBRIDIZATION; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PREVALENCE; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE; YOUNG ADULT;

EID: 84892502121     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2013.09.010     Document Type: Article

References (43)

1. Abdel-Muhsin A.A., Mackinnon M.J., Awadalla P., Ali E., Suleiman S., Ahmed S., Walliker D., Babiker H.A. Local differentiation in Plasmodium falciparum drug resistance genes in Sudan. Parasitol 2003, 126:391-400.
2. Abdel-Musin A.A., Randford-Cartwright L.C., Medani A.R., Ahmed S., Suleiman S., Khan B., Hunt P., Walliker D., Babiker H.A. Detection of mutations in the Plasmodium falcipaum dihydrpfolate reductase (dhfr) gene by-dot hybridization: a potential method for epidemiological surveys of drug resistance gene. Am. J. Trop. Med. Hyg. 2002, 67:24-27.
3. Abula T. Patient non-compliance with therapeutic regimens and the factor of noncompliance in Gondar. Ethiop. J. Health Dev. 2000, 14:1-6.
4. Abula T., Desta Z., G/Yohannes A. Prescribing patterns of drugs in medical wards of three hospitals in north-west Ethiopia. J. Ethiop. Med. Pract. 2002, 4:8-13.
5. Adhanom T., Deressa W., Witten K.H., Getachew A., Seboxa T. Malaria. Epidemiology and Ecology of Health and Disease in Ethiopia 2006, 556-576. Shama Books, Addis Ababa. 3rd ed. Y. Berhane, D. Haile-Mariam, H. Kloos (Eds.).
6. Alker A.P., Kazadi W.M., Kutelemeni A.K., Bloland P.B., Tshefu A.K., Meshnick S.R. Dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo. Trop. Med. Int. Health 2008, 13:1384-1391.
7. Bonizzoni M., Afrane Y., Baliraine F.N., Amenya D.A., Githeko A.K., Yan G. Genetic structure of Plasmodium falciparum populations between lowland and highland sites and antimalarial drug resistance in Western Kenya. Infect. Genet. Evol. 2009, 9:806-812.
8. Bray P.G., Ward S.A., O'Neill P.M. Quinolines and artemisinin: chemistry, biology and history. Curr. Top. Microbiol. Immunol. 2005, 295:3-38.
9. Bwijo B., Kaneko A., Takechi M., Zungu I.L., Moriyama Y., Lum J.K., Tsukahara T., Mita T., Takahashi N., Bergqvist Y., Björkman A., Kobayakawa T. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulphadoxine and pyrimethamine as first line treatment in Malawi. Acta Trop. 2003, 85:363-373.
10. Chen G.X., Mueller C., Wendlinger M., Zolg J.W. Kinetic and molecular properties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant clones of the human malaria parasite Plasmodium falciparum. Mol. Pharmacol. 1987, 31:430-437.
11. Eshetu T., Riha N.B., Fekadu S., Tadesse Z., Gürkov R., Hölscher M., Löscher T., Miranda I.B. Different mutation patterns of Plasmodium falciparum among patients in Jimma University Hospital, Ethiopia. Malar. J. 2010, 9:226.
12. Federal Democratic Republic of Ethiopia MOH Assessment of the therapeutic efficacy of antimalarial drugs in Ethiopia 2004, Malaria & Other Vector-Borne Diseases Prevention & Control Team Disease Prevention & Control Department, Federal Ministry Of Health, Addis Ababa.
13. Federal Democratic Republic of Ethiopia MOH Guidelines for malaria epidemic prevention and control in Ethiopia 2004, Federal Democratic Republic of Ethiopia MOH, Addis Ababa, Ethiopia.
14. Garg S., Saxena V., Kanchan S., Sharma P., Mahajan S., Kochan D., Das A. Novel point mutations in sulfadoxine resistance genes of Plasmodium falciparum from India. Acta Trop. 2009, 110:75-79.
15. Gebre-Mariam N. Malaria. The Ecology of Health and Disease in Ethiopia 1998, 136-150. Ministry of Health, Addis Ababa. First edition. Z.A. Zein, H. Kloos (Eds.).
16. Gebru-Woldearegai T.M., Hailu A., Grobusch M.P., Kun J.F.J. Molecular surveillance of mutations in dihydrofolate reductase and dihyropteroate synthase genes of Plasmodium falciparum in Ethiopia. Am. J. Trop. Med. Hyg. 2005, 73:1131-1134.
17. Hamel M.J., Greene C., Chiller T., Ouma P., Polyak C., Otieno K., Williamson J., Shi Y.P., Feikin D.R., Marston B., Brooks J.T., Poe A., Zhou Z., Ochieng B., Mintz E., Slutsker L. Does cotrimoxazole prophylaxis for the prevention of HIV associated opportunistic infections select for resistant pathogens in Kenyan adultsα. Am. J. Trop. Med. Hyg. 2008, 79:320-330.
18. International Atomic Energy Agency (IAEA) Technical Manual Standard Operating Procedures for Regional Project 6025. Detection of drug-resistant malaria. Version 1 2003.
19. Jima D., Tesfaye G., Medhin A., Kebede A., Argaw D., Babaniyi O. Efficacy of sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Ethiopia. East. Afr. Med. J. 2005, 82:391-395.
20. Kublin J.G., Dzinjalamala F.K., Kamwendo D.D., Malkin E.M., Cortese J.F., Martino L.M., Mukadam R.A., Rogerson S.J., Lescano A.G., Molyneux M.E., Winstanley P.A., Chimpeni P., Taylor T.E., Plowe C.V. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 2002, 185:380-388.
21. Kublin J.G., Cortese J.F., Njunju E.M., Mukadam R.A., Wirma J.J., Kazembe P.N., Djimde A.A., Kouriba B., Taylor T.E., Plowe C.V. Re-emergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J. Infect. Dis. 2003, 187:1870-1875.
22. Lee K., Cox-Singh J., Singh B. Morphological features and differential counts of Plasmodium knowlesi parasites in naturally acquired human infections. Malar. J. 2009, 8:73.
23. Malamba S.S., Mermin J., Reingold A., Lule J.R., Downing R., Ransom R., Kigozi A., Hunt B.M., Hubbard A., Rosenthal P.J., Dorsey G. Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. Am. J. Trop. Med. Hyg. 2006, 75:375-380.
24. Malenga G., Wirima J., Kazembe P., Nyasulu Y., Mbvundula M., Nyirenda C., Sungani F., Campbell C., Molyneux M., Bronzan R., Dodoli W., Ali D., Kabuluzi S. Developing national treatment policy for falciparum malaria in Africa: Malawi experience. Trans. R. Soc. Trop. Med. Hyg. 2009, 103S. S15-18.
25. Mita T., Tanabe K., Kita K. Spread and evolution of Plasmodium falciparum drug resistance. Parasitol. Int. 2009, 58:201-209.
26. Mula P., Fernandez-Martinez A., de Lucio A., Ramos J.M., Reyes F., Gonzalez V., Benito A., Berzosa P. Detection of high levels of mutation involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at rural hospital in southern Ethiopia. Malar. J. 2011, 10:214.
27. Ouellette M. Biochemical and molecular mechanisms of drug resistance in parasites. Trop. Med. Int. Health 2001, 6:874-882.
28. Peterson D.S., Milhous W.K., Wellems T.E. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:3018-3022.
29. Plowe C.V., Djimde A., Bouare M., Doumbo O., Wellems T. Pyrimethamine and proguanil resitance-confrerring mutations in plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for survillience in Africa. Am. J. Trop. Med. Hyg. 1995, 52:565-568.
30. Plowe C.V., Cortese J.F., Djimde A., Nwanyanwu O.C., Watkins W.M., Winstanley P.A., Estrada-Franco J.G., Mollinedo R.E., Avila J.C., Cespedes J.L., Carter D., Doumbo O.K. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J. Infect. Dis. 1997, 176:1590-1596.
31. Raman J., Sharp B., Kleinschmidt I., Roper C., Streat E., Kelly V., Barnes K.I. Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique. Am. J. Trop. Med. Hyg. 2008, 78:256-261.
32. Schunk M., Kumma W.P., Miranda I.B., Osman M.E., Roewer S., Alano A., Loscher T., Bienzle U., Mockenhaupt F.P. High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia. Malar. J. 2006, 5:54.
33. Sibley C.H., Hyde J.E., Sims P.F., Plowe C.V., Kublin J.G., Mberu E.K., Cowman A.F., Winstanley P.A., Watkins W.M., Nzila A.M. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what nextα. Trends Parasitol. 2001, 17:582-588.
34. Spalding M.D., Eyase F.L., Akala H.M., Bedno S.A., Prigge S.T., Coldren R.L., Moss W.J., Waters N.C. Increased prevalence of the Pfdhfr/Pfdhps quintuple mutant and rapid emergence of Pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya. Malar. J. 2010, 9:338.
35. Talisuna A.O., Langi P., Mutabingwa T.K., Watkins W., Van Marck E., Egwang T.G., D'Alessandro U. Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda. Trans. Roy. Soc. Trop. Med. Hyg. 2003, 97:338-342.
36. Tulu A.N. The Ecology of Health and Disease in Ethiopia 1993, 341-352. West View Press, Boulder. H. Kloos, Z.A. Zein (Eds.).
37. Wang X., Mu J., Li G., Chen P., Guo X., Fu L., Chen L., Su X., Wellems T.E. Decreased prevalence of the Plasmodium falciparum chloroquine resistance transporter 76T marker associated with cessation of chloroquine use against P. falciparum malaria in Hainan, People's Republic of China. Am. J. Trop. Med. Hyg. 2005, 72:410-414.
38. Wang P., Nirmalan N., Wang Q., Sims P.F., Hyde J.E. Genetic and metabolic analysis of folate salvage in the human malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol. 2004, 135:77-87.
39. Basic Malaria Microscopy. Part 1 Learner's Guide. 1991, 4-48. WHO, World Health Organization, Geneva, Switzerland.
40. Worku S., Girma T., Shiferaw Y. Therapeutic efficacy of sulfadoxine/pyrimethamine in the treatment of uncomplicated malaria in children. Ethiop. J. Health Dev. 2005, 19:11-15.
41. Yuthavong Y. Basis for antifolate action and resistance in malaria. Microbes Infect. 2002, 4:175-182.
42. Yuvaniyama J., Chitnumsub P., Kamchonwongpaisan S., Vanichtanankul J., Sirawaraporn W., Taylor P., Walkinshaw M.D., Yuthavong Y. Insights into antifolate resistance from malarial DHFR-TS structures. Nat. Struct. Biol. 2003, 10:357-365.
43. Zeresenay D., Abula T., G/Yohannes A., Alemayehu W. Drug prescribing patterns of outpatients in three hospitals in north-west Ethiopia. Ethiop. J. Health Dev. 2002, 16:183-189.